MEIP - MEI Pharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
MEIP price evolution
MEIP
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.37 | $5.17 | ||
| Short term investments | $54.18 | $54.31 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $27.75 | $40.77 | $59.37 | $66.17 |
| Long term investments | ||||
| Property, plant & equipment | $0.01 | $0.61 | $11.89 | $12.37 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $11.89 | $12.37 | ||
| Total investments | $54.18 | $54.31 | ||
| Total assets | $27.75 | $41.38 | $71.26 | $78.54 |
| Current liabilities | ||||
| Accounts payable | $0.98 | $3.17 | $3.18 | $1.38 |
| Deferred revenue | ||||
| Short long term debt | $1.05 | $1.01 | ||
| Total current liabilities | $2.87 | $8.36 | $9.62 | $8.04 |
| Long term debt | $10.62 | $11.01 | ||
| Total noncurrent liabilities | $10.62 | $11.01 | ||
| Total debt | $11.67 | $12.03 | ||
| Total liabilities | $2.87 | $8.36 | $20.23 | $19.05 |
| Shareholders' equity | ||||
| Retained earnings | -$396.23 | -$388.22 | -$369.81 | -$360.69 |
| Other shareholder equity | ||||
| Total shareholder equity | $51.03 | $59.49 | ||
| (in millions $) | 30 Jul 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.91 | $153.25 | $153.43 | |
| Short term investments | $83.79 | |||
| Net receivables | $0.09 | $10.04 | $7.58 | |
| Inventory | ||||
| Total current assets | $40.77 | $107.53 | $167.13 | $164.82 |
| Long term investments | ||||
| Property, plant & equipment | $0.61 | $13.28 | $10.71 | $9.28 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $13.28 | $10.71 | $9.28 | |
| Total investments | $83.79 | |||
| Total assets | $41.38 | $120.81 | $177.84 | $174.1 |
| Current liabilities | ||||
| Accounts payable | $3.17 | $6.13 | $7.92 | $6.36 |
| Deferred revenue | $64.86 | $95.44 | $87.33 | |
| Short long term debt | $1.43 | $0.87 | $0.93 | |
| Total current liabilities | $8.36 | $20.34 | $24.44 | $30.29 |
| Long term debt | $11.3 | $8.77 | $7.37 | |
| Total noncurrent liabilities | $75.84 | $100.98 | $102.44 | |
| Total debt | $12.73 | $9.64 | $8.3 | |
| Total liabilities | $8.36 | $96.19 | $125.43 | $132.74 |
| Shareholders' equity | ||||
| Retained earnings | -$388.22 | -$406 | -$374.16 | -$327.81 |
| Other shareholder equity | ||||
| Total shareholder equity | $24.62 | $52.41 | $41.36 | |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $5.22 | $3.91 | ||
| Selling, general & administrative | $4.61 | $8.02 | ||
| Total operating expenses | $9.83 | $11.93 | ||
| Operating income | -$9.83 | -$11.93 | ||
| Income from continuing operations | ||||
| EBIT | -$9.13 | -$11.06 | ||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$9.13 | -$11.06 | ||
| Income (for common shares) | -$9.13 | -$11.06 | ||
| (in millions $) | 30 Jul 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $65.3 | $48.82 | $40.7 | $25.54 |
| Cost of revenue | $1.41 | |||
| Gross Profit | $48.82 | $40.7 | $24.13 | |
| Operating activities | ||||
| Research & development | $52.45 | $85.64 | $69.4 | |
| Selling, general & administrative | $33.13 | $30.54 | $24.41 | |
| Total operating expenses | $39.86 | $85.58 | $116.18 | $93.81 |
| Operating income | -$36.76 | -$75.48 | -$69.69 | |
| Income from continuing operations | ||||
| EBIT | -$31.84 | -$54.45 | -$50.57 | |
| Income tax expense | $0.01 | |||
| Interest expense | $3.28 | |||
| Net income | ||||
| Net income | $17.78 | -$31.84 | -$54.45 | -$50.58 |
| Income (for common shares) | -$31.84 | -$54.45 | -$50.58 | |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$9.13 | -$11.06 | ||
| Operating activities | ||||
| Depreciation | $0.47 | $0.46 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.67 | $0.85 | ||
| Total cash flows from operations | -$2.93 | -$11.05 | ||
| Investing activities | ||||
| Capital expenditures | -$0.01 | |||
| Investments | $0.12 | $24.52 | ||
| Total cash flows from investing | $14.7 | $49.14 | $0.12 | $24.52 |
| Financing activities | ||||
| Dividends paid | -$11.66 | -$11.66 | ||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$11.87 | -$11.66 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $3.25 | -$13.2 | -$2.81 | $1.8 |
| (in millions $) | 30 Jul 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$31.84 | -$54.45 | -$50.58 | |
| Operating activities | ||||
| Depreciation | $1.81 | $1.24 | $0.28 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.59 | $8.35 | $10.24 | |
| Total cash flows from operations | -$52.48 | -$48.75 | -$31.96 | |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.48 | -$0.71 | |
| Investments | $53.73 | $7.37 | $25.42 | |
| Total cash flows from investing | $49.14 | $53.69 | $6.89 | $24.71 |
| Financing activities | ||||
| Dividends paid | -$11.66 | |||
| Sale and purchase of stock | $52.9 | $3.47 | ||
| Net borrowings | ||||
| Total cash flows from financing | -$11.87 | -$0.04 | $49.05 | $3.47 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$13.2 | $1.17 | $7.2 | -$3.79 |
News
|
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
Insider Monkey via Yahoo Finance
9 Mar 2024
|
|
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance
14 Feb 2024
|
|
Is MEI Pharma (MEIP) Attractively Priced?
Insider Monkey via Yahoo Finance
8 Feb 2024
|
|
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
Zacks via Yahoo Finance
10 Nov 2023
|
|
Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally
Zacks via Yahoo Finance
8 Nov 2023
|
|
Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View
Zacks via Yahoo Finance
8 Nov 2023
|
|
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
Zacks via Yahoo Finance
3 Nov 2023
|
|
Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates
Zacks via Yahoo Finance
3 Nov 2023
|
|
Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View
Zacks via Yahoo Finance
3 Nov 2023
|
|
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
Zacks
2 Nov 2023
|
Fundamentals
| Market cap | $16.66M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 6.66M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.66 |
| Quick ratio | N/A |